Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $36.3333.

A number of equities research analysts recently commented on ATOS shares. Weiss Ratings upgraded Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright boosted their target price on Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Ascendiant Capital Markets decreased their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. &PARTNERS acquired a new position in Atossa Genetics in the fourth quarter valued at about $25,000. Hudson Bay Capital Management LP acquired a new position in Atossa Genetics in the second quarter valued at about $26,000. Gallagher Capital Advisors LLC acquired a new position in Atossa Genetics in the third quarter valued at about $27,000. JPMorgan Chase & Co. grew its stake in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares during the period. Finally, Bank of America Corp DE grew its stake in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares during the period. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics Trading Down 3.1%

NASDAQ ATOS opened at $4.70 on Thursday. The stock has a 50-day simple moving average of $5.25 and a 200 day simple moving average of $7.19. The company has a market capitalization of $40.47 million, a PE ratio of -1.46 and a beta of 1.24. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Friday, May 8th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). As a group, sell-side analysts predict that Atossa Genetics will post -4.41 earnings per share for the current fiscal year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.